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Abstract
Children and adolescents with gender and sex diversity include (1) gender-nonconforming and transgender in-
dividuals for whom gender identity or expression are incongruent with birth-assigned sex (heretofore, transgen-
der) and (2) individuals who have differences in sex development (DSD). Although these are largely disparate
groups, there is overlap in the medical expertise necessary to care for individuals with both gender and sex di-
versity. In addition, both groups face potential infertility or sterility as a result of desired medical and surgical ther-
apies. The Ann & Robert H. Lurie Children’s Hospital of Chicago (Lurie Children’s) gender and sex development
program (GSDP) provides specialized multidisciplinary care for both transgender and DSD patients. In response
to patient concerns that recommended medical treatments have the potential to affect fertility, the Lurie Child-
ren’s GSDP team partnered with experts from the Oncofertility Consortium at Northwestern University to expand
fertility preservation options to gender and sex diverse youth. This article summarizes the results of a meeting of
experts across this field at the annual Oncofertility Consortium conference with thoughts on next steps toward a
unified protocol for this patient group.
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Introduction
Oncofertility emerged over the last decade as a field that
aims to preserve fertility for cancer patients undergo-
ing treatments, including chemotherapy and radia-
tion, which can lead to infertility.1,2 To expand fertility
preservation to gender and sex diverse individuals, the
Lurie Children’s gender and sex development program
(GSDP) team took the following initial steps: (1) dis-
cussed formative experiences with the leaders in the
Oncofertility Consortium, (2) reviewed the limited re-
search available on fertility in transgender and DSD pa-
tient populations, and (3) mapped the issues faced in
expanding fertility preservation to individuals with gen-
der and sex diversity. Specifically, the Lurie Children’s
GSDP team documented risks of infertility, the effects
of medical and surgical intervention, and psychosocial
concerns and ethical considerations in each population.
Although members of both the transgender and DSD
communities face infertility, the reasons for fertility chal-
lenges largely differ between the twogroups. Transgender
youth possess inherently normal reproductive capability,
but face potential infertility as a result of medical treat-
ments intended to facilitate phenotypic transition to an
affirmed gender. Pubertal suppression treatment, pre-
scribed to youthwith gender dysphoria as early asTanner
stage 2 of puberty, pauses the development of an unde-
sired puberty, including some irreversible secondary sex-
ual characteristics, but also prevents maturation of
primary oocytes and spermatogonia to mature oocytes
and sperm. Gender-affirming hormone treatment with
exogenous estrogen and testosterone in adolescence
may affect fertility, but the threshold at which sex steroid
treatment impairs fertility is unknown.3
In contrast, DSD conditions are often associated
with abnormal gonadal development, progressive go-
nadal failure over the first two decades of life, and/or
abnormal hormone production, all of which can cause
infertility.3 Furthermore, DSD conditions may be asso-
ciated with elevated risk for germ cell cancer4; thus, tra-
ditionally, gonadectomy was recommended for some
DSD conditions, in which infertility was presumed
and risk of germ cell cancer was high.
From these early efforts, the Lurie Children’s GSDP
team synthesized six representative clinical scenar-
ios (Figs. 1 and 2) to promote discussion. Appreciating
the need to gather further expertise, a working group
session about fertility preservation for individuals with
gender and sex diversity was convened at the November
2015 Oncofertility ConsortiumMeeting in Chicago, Illi-
nois. Attendees included those with expertise in fertility
preservation and/or clinical treatment of transgender
and DSD patients, with foundational training in the fol-
lowing disciplines: bioethics, reproductive endocrinol-
ogy, pediatric psychology, pediatric urology, pediatric
and adolescent gynecology, pediatric endocrinology,
and adolescent medicine. Each scenario in Figures
1and 2 was discussed with particular emphasis on tech-
nical needs, necessary team members, psychosocial
concerns, ethical concerns, and barriers to care, includ-
ing the cost of procedures. Proceedings of the session
are summarized.
Fertility Preservation Options
for Postpubertal Youth
Individuals who have completed pubertal development
are reproductively mature. For those with ovarian tissue,
options for fertility preservation include the following:
(1) embryo banking, which requires hormonal stimula-
tion for retrieval and a suitable sperm donor, (2) oocyte
banking, also requiring hormonal stimulation for re-
trieval, and (3) ovarian tissue cryopreservation, which
requires retransplantation in the future, or in vitro mat-
uration techniques, which are currently experimental.5
While still experimental, there have been at least 60
live births following tissue transplant and either
in vitro fertilization with induction of oocyte maturation
or natural pregnancies.6 For those with testicular tissue,
sperm is obtained for cryopreservation through mastur-
bation or testicular sperm extraction. Testicular tissue
cryopreservation is also possible, but as with ovarian tis-
sue cryopreservation, remains investigational.7
Special considerations for transgender youth
Attendees discussed scenarios 1a–b noting that postpu-
bertal transgender youths face specific challenges sur-
rounding fertility preservation. First, given that the
threshold atwhich gender-affirminghormones affect fer-
tility is unknown, optimal timing for fertility preserva-
tion is likely before initiation of hormone treatment
and, therefore, pursuing preservation procedures may
delay hormone treatment. It can take several weeks
from the time a patient expresses interest in fertility pres-
ervation to actually moving forward with scheduled pro-
cedures. In addition, an oocyte harvesting cycle,
specifically, requires on average an additional 2 weeks
and hormonal stimulation of the ovaries. Transgender
individuals often experience long-standing gender dys-
phoria andmay find delaying gender-affirming hormone
treatment, even by a few weeks, distressing. Further-
more, among transmasculine individuals, hormonal
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stimulation of the ovaries results in increased estrogen,
which patients may find unacceptable.
Second, the techniques required for preservation are
invasive and may exacerbate body dysphoria, which is
frequently present among transgender individuals.
Oocyte harvesting requires vaginal penetration for ul-
trasound monitoring and for oocyte retrieval. The sim-
plest method of sperm retrieval is by masturbation.
Such penetration or stimulation of anatomy incongru-
ent with gender identity may be particularly distressing.
Third, the harvested gametes will not match gender iden-
tity. To our knowledge, no qualitative studies exist that
examine whether the type of gametes to be harvested
would impact an individual’s choice to pursue fertility
preservation. There have been documented cases of
biological parenthood in transgender individuals,8
FIG. 1. Transgender fertility preservation scenarios.
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suggesting that congruence between gamete type and
gender identity is not necessary for individuals who
choose to pursue genetic parenthood.
Special considerations for youth with differences
in sex development
Review of scenarios 2 a and b elicited issues specific to
postpubertal youth with DSD. As noted above, reduced
inherent fertility potential is a strong possibility in
some DSD conditions, thus there is no guarantee of
viable oocytes or sperm. Premature gonadal failure is
common; however, due to variation in timing, the win-
dow of opportunity for preservation is unpredictable.
Moreover, youth and parents may be heavily burdened
as they consider the complicated topic of fertility pres-
ervation while weighing the risks and benefits of poten-
tial gonadectomy to prevent germ cell cancer. Also
specific to this population, many DSD conditions are
known to be caused by a genetic mutation, with the
possibility of transmission to offspring. As such, it is
FIG. 2. DSD fertility preservation scenarios. DSD, differences in sex development.
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important to discuss risk for intergenerational trans-
mission of DSD and availability of preimplantation ge-
netic screening. As with the transgender population,
gametes may not match gender identity. Anecdotally,
DSD clinical care providers have expressed concern
that patients and families may struggle to conceptualize
the use of gametes incongruent with gender identity,
but studies have not evaluated this question, thus the
implications on an individual’s decision to pursue fer-
tility preservation are unknown. Finally, timing of DSD
diagnosis may influence an individual’s willingness to
carefully evaluate options for fertility preservation.
Many of these conditions are detected during adoles-
cence, a developmental period that is critical for iden-
tity formation9 and during which sensitivity to privacy
and emotional and cognitive functioning is particularly
essential.10 Adolescence also marks a developmental
period during which sexuality and sexual identity are
explored.11 As such, a DSD diagnosis, particularly
one in which an individual’s gonads are incongruent
with gender identity and assigned sex at birth (e.g.,
Complete Androgen Insensitivity Syndrome), may
devastate an adolescent’s sense of personal identity
and self-esteem10 precluding careful consideration of
options for fertility preservation.
Fertility Preservation Options
for Pre- and Peripubertal Youth
Maturation of gametes occurs during puberty, as
shown in Figure 3. For individuals who have reached
Tanner Stage 3–4, mature oocytes or sperm may be
present, allowing preservation options similar to post-
pubertal youth. Individuals who have not yet reached
sexual maturity, however, do not possess mature oo-
cytes or sperm and are, therefore, limited in options
for fertility preservation (see scenarios 1c,d, and 2c).
Ovarian and testicular tissue may be harvested through
biopsy or gonadectomy and cryopreserved. The first
live birth following ovarian tissue autotransplantation
from a pubertal, but premenarchal girl, was recently
reported; thus, this may increasingly become an op-
tion.12 In vitro follicle growth of ovarian tissue or mat-
uration of sperm, however, remains investigational. As
such, attendees unanimously agreed that such proce-
dures must be performed under a protocol approved
by an institutional review board (IRB) at an institution
with expertise in these techniques. Protocols should be
specific to the population, either gender or sex diverse
youth. Inclusive language, such as gonad, rather than
ovary or testicle, allows for preservation of either type
of tissue, regardless of gender identity and is inclusive
of individuals with ovotesticular DSD, who possess
both ovarian and testicular tissue.
Special considerations for transgender youth
Considerations specific to pre- and peripubertal trans-
gender youth with gender dysphoria include decisions
about whether and when to pursue medical treatment
to facilitate physical transition. Current guidelines for
medical treatment of transgender youth with gender
FIG. 3. Spermatogenesis and oogenesis.
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dysphoria recommend gonadotropin releasing hor-
mone agonists (GnRHa) to pause pubertal develop-
ment among early pubertal youth as early as Tanner
Stages 2–3.13 Pubertal suppression may alleviate psy-
chological distress related to ongoing or anticipated pu-
bertal changes, prevent progression of secondary sexual
characteristics incongruent with affirmed gender iden-
tity, allow time for further exploration of gender iden-
tity, and provide families more time for discussion and
decision-making.14 Adolescents with persistent gender
dysphoria may go on to initiate later in adolescence. An
additional effect of GnRHa, however, is preventing
maturation of germ cells, which could be used for bio-
logical fertility potential. Preservation of ovarian or tes-
ticular tissue using IRB-approved protocol could be
pursued any time before the use of gender-affirming
hormones. Alternatively, the adolescent could allow
some pubertal development to mature gametes, before
hormone treatment, but there was consensus that this
option would likely be less desirable to the youth and
antithetical to the use of GnRHa for prevention of sec-
ondary sexual characteristics. The group agreed that
discussion of the fertility effects of GnRHa therapy
should begin before starting treatment. The gender
care provider most well-known to the individual and
family should initiate and repeat these discussions.
Ideally, these conversations would also take place
with the individual’s mental health provider during
the recommended assessment of readiness for medical
interventions as outlined by WPATH15 and Endocrine
Society clinical practice guidelines.13
Special considerations in youth with differences
in sex development
As for postpubertal individuals with DSD, pre- and
peripubertal youth with DSD may face uncertainty
about inherent fertility potential and potential gonadal
insufficiency. The group agreed that these questions
complicate recommendations for the optimal timing
of fertility preservation. Preliminary discussions may
begin shortly after birth, in the case of an infant diag-
nosed with a DSD. Completing diagnostic testing and
understanding the nature of the DSD condition can
be a lengthy process of adjustment for parents, requiring
patience and continued discussion. Conversation about
fertility must continue in earnest if considering gonadec-
tomy. Risk of progressive gonadal failure in early child-
hood, in conditions such as XO/XY Turner Syndrome
and Klinefelter Syndrome, may advance the ideal timing
of preservation to a younger age when primary oocytes
are still present. Again, the group recognized the possi-
bility of transmitting a genetic condition to offspring,
highlighting the need to weigh this risk and consider op-
tions for preimplantation genetic screening.
Team Approach
The group recommends a team approach for discussing
and implementing fertility preservation procedures in
gender and sex diverse individuals. Working group at-
tendees offered experience with a range of institutional
practice and team members. This led to an understand-
ing that a proper fertility preservation team at one insti-
tution may be different than at another, based on the
experience and availability of providers. For example,
there can be overlap in roles of an endocrinologist and
adolescent medicine specialist in the care of transgender
youth or in surgeons’ roles given varying experience
with fertility preservation. In general, however, partici-
pants agreed that the team should include members
with training in disciplines as shown in Table 1.
In addition, the group agreed that including other
stakeholders will be essential in guiding the direction
of this field. Members of this working group are part
of the National physicians cooperative (NPC), a national
interdisciplinary group of specialists, which provides fer-
tility preservation clinical services to cancer patients, in-
cluding basic scientists, allied health professionals, and
physician groups (urology, reproductive endocrinology,
general surgery, obstetrics/gynecology, and hematolo-
gy/oncology). The NPC was born from needs associated
with cancer patients, but now extends to incorporate
other fields as fertility threats are identified. The subset
of the NPC for gender and sex diverse individuals should
seek input from youth affected by these conditions and
their parents, as well as advocate for unique and impor-
tant perspectives from those outside the medical field.
Ethical Concerns
In discussing the options for fertility preservation in
gender and sex diverse youth, the group raised many
ethical concerns. First, as in many dilemmas in the pe-
diatric population, issues arise regarding a patient’s
ability to participate meaningfully in medical decision-
making (i.e., issues related to assent versus consent).
While fertility decisions ideally are made by an individ-
ual in adulthood, postponing decision-making may re-
sult in missing an optimal window during which
fertility preservation is most likely to be successful. Sec-
ond, the fact that parents, as the legal guardian and
proxy for the youth, make decisions for their child
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can raise concerns, especially if there are divergent
views. For example, parents’ wishes may differ from
those of their child or may differ between parents shar-
ing legal decision-making rights. Third, providers may
exert pressure due to their own personal biases regard-
ing issues such as alternative options for parenting,
whether to pursue fertility preservation, and the role
of preimplantation genetic screening. Fourth, there is
great concern about the implications of encouraging
‘‘false hope’’ for fertility potential. As reviewed, fertility
potential in many of these conditions is unknown and
in vitro maturation of cryopreserved prepubertal tissue
is experimental, with no guarantee for successful future
use of preserved immature gametes. Thus, the group
suggested using the term ‘‘cryopotential,’’ rather than
cryopreservation, to denote storage of immature tissue,
where the potential for future use is still under develop-
ment. Finally, ownership of the biological material
must be established and documented before preserva-
tion. Adult individuals specify the fate of the material
in the event of their death: donation to research, to an-
other individual, or that the material be destroyed.
Embryos made with a partner’s gametes belong to the
partner. In the pediatric population, current policies
specify that in the event of death, tissue is either
destroyed or donated for research.
Technical Requirements
Success in fertility preservation is a complicated pro-
cess, dependent on multidisciplinary expertise and spe-
cific technical abilities. Thus, the group determined
that fertility preservation for gender and sex diverse in-
dividuals should be offered at centers that can provide
both clinical and technical expertise, with a designated
team leader. In addition to the team specified in Table
1, pathology expertise is also important to examine and
process the tissue and an assisted reproductive technol-
ogy and andrology laboratory to further process the
specimens. A patient navigator is extremely helpful to
guide patients through the process, and research assis-
tants are important for regulatory support in opening
and maintaining protocols, as well as collecting data.
One of the roles that the NPC played in the develop-
ment of the oncofertility field was a series of guidelines
and protocols that could be shared and adapted by
practitioners even as larger specialty societies were de-
veloping guidelines. Having team members work to-
gether across disciplines catalyzes the work.
Table 2. Cost of FP Techniques: Experience of Lurie
Children’s Hospital Oncofertility Team
Technique Cost
Insurance
coverage
Oocyte cryopreservation $5000–$10,000 No
Ovarian tissue cryopreservationa
(consultation, oophorectomy,
and freezing of ovary)
$9000–$20,000 Variable
Semen analysis $375 Usually
Freezing semen $350 No
TESE $8000 Variable
Testicular tissue
Cryopreservationa
(consultation, testicular
biopsy, or orchiectomy)
$5500 Usually
Infectious disease testing $240 Yes
Shipping to storage facility $215 No
Yearly storage $275 ($75 discount
based on financial
need)
No
aExperimental.
Table 1. Team Approach to Fertility Preservation
Discipline Role on fertility preservation team
Psychology/social work Facilitate discussion of desire for biological fertility. Assess individual’s capacity for medical decision-making, family
dynamics, and transgenerational desire for fertility. Provide support for individuals struggling to cope with
potential infertility.
Endocrinology Assess gonadal function and likelihood of biological fertility potential. Discuss fertility-related implications of
medical transition treatments in transgender youth.
Adolescent medicine Discuss fertility-related implications of medical transition treatments in transgender youth.
Urology Counsel about sperm preservation. Perform testicular biopsy, TESE. Assess internal anatomy and constitution of
gonadal tissue. Perform gonadal biopsy or gonadectomy.
Pediatric surgery Assess internal anatomy and constitution of gonadal tissue. Perform gonadal biopsy or gonadectomy.
Obstetrics/gynecology Assess internal anatomy and constitution of gonadal tissue. Perform gonadal biopsy or gonadectomy.
Reproductive endocrinology Counsel about and perform ovarian stimulation and oocyte retrieval.
Ethics Evaluate individual’s ability to assent/consent. ‘‘Arbitrate’’ in situations, in which parents and youth may disagree on
decisions for fertility preservation.
Financial counseling Discuss financial implications of procedures and storage, often not included in insurance coverage.
Genetic counseling Discuss risks of transmission of condition to offspring and role of preimplantation genetics.
Fundamental reproductive
science
Develop new technologies for measuring fertility loss and restoring endocrine and fertility in high-risk cases.
TESE, testicular sperm extraction.
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Barriers to Care
In discussing other potential barriers to care, partici-
pants identified geographic and financial concerns.
The scarcity of fertility preservation centers limits
some individuals’ ability to pursue fertility preserva-
tion, particularly if travel to a center is too burdensome.
Furthermore, the cost of the preservation process itself
may be prohibitive. Potential fees include those for har-
vesting of tissue or retrieval of gametes (operating
room, surgery, and anesthesia fees), consultation with
fertility preservation specialists, hormones to stimulate
oocyte production, tissue processing fees, and shipping
of gametes or tissue to a storage facility and long-term
storage. Insurance coverage for such procedures is ex-
tremely limited and state specific, although the Onco-
fertility Consortium has worked to address this
issue.16 Table 2 provides estimated procedure and stor-
age costs at Lurie Children’s, as well as the likelihood of
insurance coverage. It is important to note that these
cost data are institution specific and include some ne-
gotiated pricing. The notations about insurance cover-
age reflect the experience in oncofertility and may be
found to be different in the gender and sex diverse pop-
ulation. Long-term storage remains the individual’s re-
sponsibility and need-based financial assistance is
offered by some storage facilities. Limited philan-
thropic support for storage now exists for oncology pa-
tients and is a potential avenue for defraying some costs
for gender and sex diverse individuals.
Summary
The inaugural meeting of the Gender and Sex Diversity
Fertility Working Group set the stage for a new field in
fertility preservation. This report synthesizes the current
state of the field, gaps in knowledge, and goals to address
moving forward (Table 3). Ultimately, the goal of im-
proved care for these populations will be achieved
through collaborative interdisciplinary work.
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